{"id":"somatropine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Growth hormone receptor"},"_scrapedAt":"2026-03-28T01:35:29.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Growth retardation","diseaseId":"growth-retardation","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pituitary dwarfism","diseaseId":"pituitary-dwarfism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prader-Willi syndrome","diseaseId":"prader-willi-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe growth hormone deficiency in adulthood","diseaseId":"severe-growth-hormone-deficiency-in-adulthood","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Turner syndrome","diseaseId":"turner-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01626833","phase":"PHASE2, PHASE3","title":"Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-03","conditions":"Anorexia Nervosa, Interruption of Growth, Delayed Puberty","enrollment":15},{"nctId":"NCT00476385","phase":"PHASE3","title":"Practicability and Acceptability of Stylomax® in Children","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Growth Hormone Deficiency","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"OFF LABEL USE"},{"count":2,"reaction":"HEADACHE"},{"count":2,"reaction":"PAIN"},{"count":1,"reaction":"ACCIDENTAL EXPOSURE TO PRODUCT"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"BLOOD PRESSURE INCREASED"},{"count":1,"reaction":"BONE DISORDER"},{"count":1,"reaction":"CARDIAC DISORDER"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"somatropine","genericName":"somatropine","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Somatropine is a growth hormone receptor agonist, classified as an agonist drug. It is used to treat various conditions, including anorexia nervosa, growth hormone deficiency, delayed puberty, interruption of growth, osteopenia with failure of acquisition of bone mass, and growth hormone deficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}